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Abstract
Background: Amplifications of the transcription factor, SRY (sex determining region Y)-box 2 (SOX2), are common
in non-small cell lung cancer (NSCLC). SOX2 signaling is important in maintaining the stem cell-like phenotype of
cancer cells and contributes to the pathogenesis of lung cancer. TP53 is known to inhibit gene amplifications and
to repress many stem cell-associated genes following DNA damage. The aim of this study was to investigate if TP53
mutational status affected SOX2 copy number variation and gene expression in early-stage NSCLC patients;
moreover, to assess if TP53 regulates SOX2 expression in human lung cancer cells.
Methods: 258 early-stage lung cancer patients were included in the study. Exons 4–9 in the TP53 gene were
sequenced for mutations in tumor tissues. SOX2 copy number as well as TP53 and SOX2 gene expression were
analyzed in tumor and in adjacent non-tumorous tissues by qPCR. TP53 and SOX2 were silenced using gene-specific
siRNAs in human lung adenocarcinoma A427 cells, and the expression of TP53, SOX2 and subset of selected miRNAs
was analyzed by qPCR. The odds ratios (ORs) for associations between copy number variation and lung cancer were
estimated by conditional logistic regression, and the correlation between gene status and clinicopathological
characteristics was assessed by Chi-square or Fisher’s exact test. Gene expression data was analyzed using
nonparametric Mann–Whitney test.
Results: TP53 mutations were associated with an increased risk of acquiring a SOX2 copy number alteration
(OR = 2.08, 95 % CI: 1.14–3.79, p = 0.017), which was more frequently occurring in tumor tissues (34 %) than in
adjacent non-tumorous tissues (3 %). Moreover, SOX2 and TP53 expression levels were strongly correlated in
tumor tissues. In vitro studies showed that a reduction in TP53 was associated with decreased SOX2 expression in A427
cells. Furthermore, TP53 knockdown reduced the miRNA hsa-miR-145, which has previously been shown to regulate
SOX2 expression.
Conclusions: TP53 signaling may be important in the regulation of SOX2 copy number and expression in NSCLC
tumors, and the miRNA hsa-miR-145-5p may be one potential driver. This prompts for further studies on the
mechanisms behind the TP53-induced regulation of SOX2 expression and the possible importance of hsa-miR-145 in
lung cancer.
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Background
Lung cancer is the most frequent cause of cancer-
related mortality worldwide, leading to an estimated
1.4 million deaths in 2010 [1]. Smoking, occupational
and environmental exposures to chemicals are major
causes of lung cancer. Lung cancer constitutes a het-
erogeneous disease in regard to clinical presentation,
pathological features and biological behavior. The ma-
jority of cases are non-small cell lung carcinomas
(NSCLC), which comprises adenocarcinoma, squa-
mous cell carcinoma and large cell carcinoma. The
genomic alterations occurring in lung carcinomas are
very complex [2–5]. However, alterations in the TP53
gene are among the most significant genetic events in
lung cancers [6], often occurring as a response to
DNA damage caused by exposure to a variety of gen-
otoxic agents such as polycyclic aromatic hydrocar-
bons (PAHs) [7]. Mutations in the TP53 gene increase
the risk for chromosomal rearrangements, such as
copy number alterations, which are involved in the
development and progression of many human malig-
nancies including lung cancer [8]. Amplifications or
deletions in the fragile sites harboring important tran-
scription factors may further advance the process of
carcinogenesis [9].
The transcription factor SRY (sex determining re-
gion Y)-box 2, encoded by the SOX2 gene located at
the 3q25-27 region, is often altered in NSCLC [10,
11]. SOX2 has a crucial role in maintaining the stem
cell-like phenotype in cancer cells [12, 13] and con-
tributes to the pathogenesis of lung cancer by con-
trolling cell proliferation and malignant
transformation [11]. In lung cancer, SOX2 gene ampli-
fication and consequent increased expression occur
most frequently in squamous cell carcinoma [14, 15]
and to a lesser extent in adenocarcinoma [14, 16].
Interestingly, TP53 has been reported to regulate
SOX2 expression in embryonic stem cells [17] and re-
cently also in the H1299 lung carcinoma cell line
[18]. miRNAs are important mediators of TP53-
signaling and in embryonic stem cells TP53 represses
SOX2 expression through the activation of hsa-miR-145
[19–21]. This is of interest as a recent study showed that
low levels of hsa-miR-145 are associated with unfavorable
prognosis in NSCLC [22].
Given the crucial role of TP53 and SOX2 in lung cancer
and their known association in stem cell development, we
hypothesize that TP53 may have a regulatory effect on
SOX2 in lung cancer. Thus, effects of TP53 mutations on
SOX2 copy number alterations were studied in lung can-
cer tumors and correlation between the gene expression
levels investigated. Furthermore, effects of TP53 silencing
on SOX2 mRNA levels were evaluated and the possibility
of miRNAs as downstream regulators was assessed.
Methods
Cases
Early-stage lung cancer patients (n = 258) were Caucasians
of Norwegian origin admitted to Haukeland University
Hospital in Bergen between 1988 and 1994, for primary
surgery. The patients were enrolled in the study, whenever
practically feasible, and informed written consent covering
analysis of molecular and genetic markers was signed by
the patients prior to surgery. The subjects included in this
manuscript are a subgroup recruited into the project “lung
cancer genetics” at our institute. The project has been
approved by the Regional Committee for Medical and
Health Research Ethics in South Norway in accordance
with the WMA Declaration of Helsinki. The ethical
approval covered access to the NSCLC databank. The
characteristics of the patients included in the study are
summarized in Table 1. Samples of adjacent non-
tumorous lung tissue, confirmed by histology, were cut
from the lobectomi specimens at the time of surgery.
Tumor histology was confirmed by an experienced
pathologist and samples containing ≥80 % of tumor
cells were analyzed in the study. After resection tumor
Table 1 Characteristics of patients (n = 258)
Age
(Mean ± SD) 63.9 ± 10.1
(Median, min-max) 66 (25–82)
Gender (male: female) 183/74
Smokers/Non-smokers 222/22
No cigarettes per day
(Mean ± SD) 15.3 ± 7.9
(Median, min-max) 14 (2–50)
Total years of smoking
(Mean ± SD) 41.3 ± 11.6
(Median, min-max) 43 (2–69)
Total pack-years*
(Mean ± SD) 31.6 ± 18.2
(Median, min-max) 28 (1–113)
Histology
Adenocarcinoma 118 (45.7 %)
Squamous cell carcinoma 103 (39.9 %)
Large cell carcinoma 36 (13.9 %)
Others 1
PAH-DNA adducts†
(Mean ± SD) 12.3 ± 8.9
(Median, min-max) 10 (1–46)
TP53 mutated/WT 134/101
*Pack-years indicates the number of cigarettes smoked per day x number of
years smoked/20. †PAH-DNA adducts per 108 nucleotides
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and non-tumorous tissues were snap-frozen in liquid
nitrogen and kept at −80 °C until further processing.
Copy number analyses by quantitative PCR
DNA was extracted from frozen lung tissue samples
using standard proteinase K digestion followed by phe-
nol–chloroform extraction and ethanol precipitation.
Control DNA was isolated from blood samples by
Flexigene DNA kit (Qiagen, Hilden, Germany). SOX2
copy number alterations were evaluated by quantitative
real-time PCR (qPCR) using SYBR Green I technology
on an ABI PRISM® 7900HT Fast PCR System (Applied
Biosystems, Thermo Scientific, Waltham, MA, USA), as
described elsewhere [23, 24]. The multicopy gene FTH1
was used as reference gene. Primer sequences were:
SOX2 forward primer, 5’-GCTCTTGGCTCCATGGGT
TC-3’, reverse primer, 5’-GCTGATCATGTCCCGGAGG
T-3’, FTH1 forward primer, 5’-GATGATGTGGCTTTG
AAGAACTTTGCCA-3’, reverse primer, 5’-CACCTCG
TTGGTTCTGCAGCTTCATCA-3’. Primer specificity
was determined by melting point analysis. qPCR was
performed using 20 ng template DNA in a total volume
of 10 μL containing PerfeCTa SYBR Green FastMix,
ROX (QuantaBioSciences, Gaithersburg, MD, USA).
Cycling conditions were: 95 °C, 2 min followed by 40 cy-
cles of 95 °C, 10 sec and 60 °C, 45 sec. The PCR was run
in duplicates using a relative standard curve approach.
The standard curve was generated by performing serial
dilutions of plasmid DNA containing one copy of the
area of interest for each of the assayed genes. pUC57
plasmid DNA (GenScript, Piscataway, NJ,USA) was
added to each standard to maintain a constant amount
of total DNA per reaction tube. Only R2 values above
0.99 were accepted and data was quality controlled in
accordance with previous recommendations [23]. For
confirmation, analysis of >5 % of all samples was re-
peated. Control DNA isolated from cancer-free individ-
uals was used to normalize for plate variability. Copy
numbers below 1.5 and above 2.5 were defined as
deleted and amplified, respectively.
Analysis of frequency of TP53 mutations and PAH-DNA
adduct levels
To assess the frequency of TP53 mutations in tumor
tissues DNA was screened either by single-strand con-
formational polymorphism or denaturating capillary elec-
trophoresis as previously described, covering exons 4 to 9
of the TP53 gene, and DNA samples with alterations were
sequenced [25, 26]. PAH-DNA adduct levels were deter-
mined in non-tumorous lung tissue by 32P-postlabelling as
previously published [27]. The patients were divided into
two groups on the basis of having levels greater than or
less than the median (9.91) of DNA adducts per 108
nucleotides.
Cell culture and RNA knockdown
Lung adenocarcinoma A427 cells were maintained in
RPMI-1640 medium (Thermo Scientific) with 10 % FCS
(Thermo Scientific), and penicillin/streptomycin (Biowest
SAS, Nuaillé, France) in 5 % CO2 at 37 °C. The cells were
passaged every third day and passage numbers between 25
and 30 were used in all experiments. In RNA knockdown
experiments 100000 cells/mL were seeded in 2 mL growth
medium without penicillin/streptomycin in 6-well plates.
For protein isolation 200000 cells/mL were seeded in
10 mL medium without penicillin/streptomycin in 10 cm2
plates. siRNA targeting human TP53, SOX2 and non-
target (control) were purchased from Applied Biosystems
(Thermo Scientific). Transfections were performed 24 h
after seeding using 10 nM siRNA and Lipofectamin
RNAiMAX reagent (Invitrogen, Thermo Scientific) ac-
cording to manufacturer’s instructions. The cells were
harvested 48 h after transfection to analyze RNA,
miRNA and protein expression.
Western blotting
Nuclear proteins were extracted from knockdown and
control A427 cells using NE-PER Nuclear and Cytoplas-
mic extraction reagents (Thermo Scientific, Rockford, IL,
USA). Protein concentrations were determined by BCA
Protein Assay (Thermo Scientific) and 40 µg lysate was
separated by 10 % SDS-PAGE and transfer to a Immobi-
lon PVDF membrane (Millipore, Bedford, MA, USA). To
prevent non-specific background binding, the membranes
were incubated with 5 % non-fat milk in Tris-buffered
saline with 0.05 % Tween-20 (TBST) for 1 h at room
temperature. Membranes were incubated with primary
antibodies against SOX2 and TP53 (Cell Signaling tech-
nology Inc., Beverly, MA, USA) over night at 4 °C and
against GAPDH (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) for 1 h at room temperature. After washing
three times with TBST, the membranes were incubated
with secondary anti-rabbit antibody (Cell Signaling) for
1 h at room temperature and proteins visualized by Super-
Signal West Pico Chemiluminescent Substrate (Thermo
Scientific). Semiquantitative densitometry analysis were
performed using Image J.
Gene expression analysis
Total RNA was isolated from frozen lung tissue samples
using standard Trizol extraction and total RNA from
transfected cells was isolated using NucleoSpin miRNA
(Macherey-Nagel, Duren, Germany). RNA was DNase
treated with DNA-free kit (Ambion, Thermo Scientific)
and its quality was assessed by 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA). For gene expression
analysis total RNA was reversed transcribed using qScript
cDNA Supermix or qScript cDNA synthesis kit (Quanta
BioSciences) for tissue samples and cells respectively.
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Beta-Actin (ACTB) was used as reference gene. Primer se-
quences were: SOX2 forward primer, 5’-GGGGAAAG-
TAGTTTGCTGCC-3’, reverse primer, 5’-CGCCGCCGA
TGATTGTTATT-3’, TP53 forward primer, 5’-CCATCCT
CACCATCATCACA-3’, reverse primer, 5’-CACAAAC
ACGCACCTCAAAG-3’, ACTB forward primer, 5’-GCG
AGAAGATGACCCAGATCA-3’, reverse primer, 5’-GATA
GCACAGCCTGGATAGCAA-3’. TargetScan 6.2 (http://
www.targetscan.org/) was used to predict conserved
miRNA binding sites in the SOX2 gene. Of these five pre-
viously known targets of TP53; hsa-miR-145-5p, hsa-miR-
145-3p, hsa-miR-200b-3p, hsa-miR-200c-3p, hsa-miR-
429-1p; were selected for further analysis. Accordingly,
total RNA was reversed transcribed using qScript micro-
RNA cDNA Synthesis Kit (Quanta BioSciences) and ex-
pression was analyzed using commercial primers
(Integrated DNA Technologies, Leuven, Belgium). SNO
and RNU6 were used as references. Expression was evalu-
ated by qPCR using SYBR Green I technology on an ABI
PRISM® 7900HT Fast Real-Time PCR System (Applied
Biosystems, Thermo Scientific). Primer specificity was de-
termined by melting point analysis.
Statistical analysis
Statistical analyses were carried out using IBM SPSS
software version 22.0. Associations between copy num-
ber variation and lung cancer were estimated by odds
ratios (ORs) and their 95 % confidence intervals (CIs)
from conditional logistic regression adjusted for age,
gender, total pack-years and tumor histology. The total
number of patients included in the study was 258. How-
ever, for some patients, data on smoking status, gender
or age was missing, and for five patients CNV data was
not successfully obtained, thus giving a reduced number
of patients included in the final statistical analysis.
Effects of clinicopathological data on gene status were
assessed by Chi-square or Fisher’s exact test for categor-
ical variables and by nonparametric tests for ordinal
variables. Cancer free survival was obtained from 241
patients by Kaplan Meier analysis. Expression data
was analyzed using nonparametric Mann–Whitney
test or one-way ANOVA. p < 0.05 was considered
significant.
Results
SOX2 copy number alterations are frequent in NSCLC
tumors
Analyses of gene copy numbers were performed on
DNA from paired non-tumorous and tumor tissue of
the same patient in order to evaluate whether genomic
variations in SOX2 may be associated with lung tumor
development. The SOX2 copy number alterations were
more frequent in tumors than in non-tumorous tissues
of NSCLC patients (Fig. 1a). The odds for acquiring a
copy alteration in SOX2 were 12.6-fold higher (95 % CI:
5.8–27.1) in tumors than in non-tumorous tissues. SOX2
gene amplifications were observed in 33.6 % of tumors
compared with 3.2 % in the adjacent non-tumorous tis-
sues (OR: 15.7, 95 % CI: 6.3–39.1, p < 0.001). A low oc-
currence of SOX2 gene deletions was also observed in
6.1 % of tumors (OR: 6.0, 95 % CI: 1.6–23.0, p = 0.009).
Amplifications of >5 copies were observed in 15 of 81
tumors with a SOX2 amplification (Fig. 1b), and SOX2
copy number alterations were most frequent in squa-
mous cell carcinoma (Fig. 1c). Moreover, changes in
SOX2 gene status were more frequent in smokers than
non-smokers (p = 0.015, Additional file 1: Table S1).
SOX2 mRNA expression levels were investigated in 15
tumor and 15 non-tumorous tissue samples, and a
strong correlation, (r = 0.875, p = 0.001), was observed
between the SOX2 copy numbers and the relative SOX2
mRNA expression level (Fig. 1d). SOX2 copy number al-
terations did not affect the survival of the patients (data
not shown).
Mutations in TP53 gene increase frequency of SOX2 copy
number alterations
The effects of TP53 mutations on SOX2 copy number
were investigated in 229 tumor tissues of the NSCLC pa-
tients. Of these, 56.8 % had at least one mutation in their
lung tumors. Patients with mutated TP53 had a signifi-
cantly higher odds of acquiring a copy number variation
in SOX2 (OR = 2.08, 95 % CI: 1.14-3.79, p = 0.017) than
patients without TP53 mutations (Fig. 2a). Furthermore,
a positive correlation (r = 0.447, p = 0.013) was observed
between TP53 and SOX2 mRNA expression levels in a
subset of cancer patients (n = 30, Fig. 2b). TP53 mutations
are often occurring as a consequence of DNA-adduct for-
mation following exposure to genotoxic carcinogens such
as PAHs in cigarette smoke. However, increased PAH-
adduct levels did not increase the occurrence of
SOX2 copy number alterations in our material (data
not shown), despite a higher frequency of SOX2 gene
alterations in smokers compared to the non-smoking
NSCLC patients.
TP53 affects SOX2 expression and hsa-miRNA-145-5p
levels in human lung cells in vitro
To investigate the effect of TP53 on SOX2 expression in
NSCLC, the TP53 gene was silenced in the lung adenocar-
cinoma A427 cell line using siRNA. Effective knockdown
of TP53 and SOX2 proteins after 48 h was confirmed
in three independent experiments by western blotting
(Fig. 3a). In TP53 knockdown cells a significant 40 %
reduction in SOX2 mRNA and protein expression
was observed (p = 0.001, Fig. 4a and p = 0.01, Fig. 3b).
SOX2 knockdown did not affect the expression of
TP53 (Fig. 4b). Moreover, hsa-miR-145-5p expression
Samulin Erdem et al. BMC Cancer  (2016) 16:28 Page 4 of 9
Fig. 1 SOX2 copy number alterations in lung tumors (n = 244). a Percentage of SOX2 gene amplifications and deletions in lung tumors
and non-tumorous tissues. b Distribution of SOX2 copy numbers in lung tumors. More than 2.5 copy numbers were defined as amplifications,
whereas less than 1.5 copy numbers were defined as deletions. c Distribution of copy number alterations between NSCLC of different histology.
AD: adenocarcinoma, SQ: squamous cell carcinoma and LC: large cell carcinoma. d Correlation between the relative genomic SOX2 levels
and its mRNA expression. r = 0.875, p < 0.001 was obtained from Spearman's Rank-Order Correlation (n = 30)
Fig. 2 a TP53 gene status in tumor tissue of patients and its association with copy number alterations (CNA) in the SOX2 gene. **p = 0.017, was
obtained from unconditional logistic regression, adjusted for age, gender, total pack-years and histology (n = 229). b Correlation between the relative
SOX2 and TP53 mRNA expression. r = 0.447, p = 0.013 was obtained from Spearman's Rank-Order Correlation (n = 30)
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was significantly reduced in TP53 knockdown cells (p =
0.004, Fig. 4a). In contrast, the levels of hsa-miR-145-3p,
hsa-miR-200b and hsa-miR-200c remained unchanged in
TP53 knockdown cells, whereas hsa-miR-429 was not
expressed in these cells (data not shown).
Discussion
SOX2 has a crucial role in maintaining the stem cell-like
phenotype in cancer cells [12, 13] and its overexpression
is generally associated with aggressive disease and poor
outcome in several different tumor types [28–32]. SOX2
has been identified as the driving gene of the 3q25-27
amplicon, which is common in most NSCLC cases and
contributes to the pathogenesis of lung cancer by con-
trolling cell proliferation and malignant transformation
[11]. Comparison of tumor tissue with non-tumorous
tissue obtained from the same patients confirmed that
tumor tissues had significantly higher odds of acquiring
a copy number alteration in the SOX2 gene. Surprisingly,
SOX2 copy number deletions were detected in a subset
of tumor samples in this cohort. Deletions in SOX2 copy
number have not previously been reported in NSCLC
and the importance of this finding remains to be eluci-
dated. SOX2 gene amplifications were observed in 34 % of
tumors in this study. SOX2 has been shown to be highly
expressed in approximately 90 % of pulmonary squamous
cell carcinoma and to a lesser extent in adenocarcinoma
[16] and several studies have previously identified SOX2
gene amplifications in lung squamous cell carcinomas with
reported frequencies from 20 % to 60 % [13, 15, 33–36].
Here, we observed higher frequency of SOX2 copy number
amplifications in squamous cell carcinoma tumors (59 %)
than in adeno- (20 %) or large cell carcinoma (34 %).
These data are in line with previous reports indicating a
role for SOX2 in carcinogenesis. Accordingly, SOX2 af-
fects tumorigenesis and its overexpression increases cell
Fig. 3 a Efficient SOX2 and TP53 knockdown was confirmed by
western blotting. SOX2 and TP53 were silenced using siRNA technology.
After 48 h nuclear lysates were isolated from knockdown and control
cells. 40 µg lysate/lane was resolved in a SDS-PAGE and membrane
analysed for expression of SOX2, TP53 and GAPDH (loading control) by
western blotting. b Protein expression was semiquantitatively analysed
by densitometry using Image J. Bars indicate mean ± SE, n = 3.
***indicating p < 0.001 and **indicating p < 0.01 was obtained
from one-way ANOVA
Fig. 4 Effects of silencing of the TP53 and SOX2 genes on the expression of SOX2, TP53 and hsa-miRNA-145-5p in pulmonary adenocarcinoma A427
cells. a TP53 was silenced using siRNA technology and expression of SOX2 and hsa-miR-145-5p was analyzed by qPCR. Bars indicate mean ± SE, n = 9
and n = 12 for SOX2 and hsa-miR-145-5p, respectively. b SOX2 was silenced using siRNA technology and expression of TP53 was analyzed by qPCR.
Bars indicate mean ± SE, n = 9. ***indicating p < 0.001 and **indicating p < 0.01 was obtained from nonparametric Mann–Whitney test
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migration and colony formation, while its knockdown
impairs cell growth and suppresses metastasis of lung
cancer cells [35, 37–39]. Increased SOX2 expression
is associated with metastatic progression [40] and
SOX2 gene amplifications are more frequent in high-
grade than low-grade lesions [41]. Moreover, condi-
tional homozygous overexpression of SOX2 in murine
Clara cells induces bronchial epithelial hyperplasia
with progression to lung cancer in approximately
50 % of the animals [42]. Taken together, these results
support the hypothesis that SOX2 may act as an
oncogene in lung carcinogenesis.
The prognostic role of SOX2 in NSCLC remains uncer-
tain as conflicting data has been reported. SOX2 amplifica-
tions and overexpression have been reported as predictors
of prolonged survival in squamous cell carcinomas [15, 43].
On contrary, SOX2 expression is suggested a poor
prognosis predictor in stage I lung adenocarcinoma [44].
Wilbertz et al. investigated SOX2 amplifications and
expression in two cohorts and reported no association
between SOX2 expression and survival in lung adenocar-
cinoma; however, observed a decreased survival in pa-
tients with low-level amplifications in one of the cohorts
[15]. Differences in biological properties of tumor-
initiating cancer stem cells in squamous cell carcinoma
compared to lung or breast adenocarcinoma have been
suggested as an explanation to the different observed asso-
ciations between SOX2 gene amplifications and prognosis
[45]. Recently, several studies have showed improved out-
come as a consequence of SOX2 gene amplification in
NSCLC, independent of histological subtype [14, 46, 47].
In our study, no significant effect on survival rates could
be demonstrated, but this may be due to limited number
of patients investigated. Moreover, differences in patient
clinical characteristcs, methodology and scoring criteria
might explain some of the reported discrepancies. Clearly,
more studies are needed to elucidate the role of SOX2 in
lung cancer progression and prognosis.
TP53 has been demonstrated to down-regulate several
stem cell-associated genes, including SOX2, following
DNA damage in embryonic stem cells [17]. Moreover, a
recent report indicated that induction of TP53 led to
repressed SOX2 expression in NSCLC cells [18]. Since
genetic alterations in the TP53 gene are significant
events in lung cancers [6], and mutations in the TP53
gene increase the risk for chromosomal rearrangements
such as copy number alterations [8], these early reports
open up the possibility of TP53 as an important regula-
tor of SOX2 in NSCLC. To address this, the effects of
TP53 mutational status on SOX2 copy number and
expression levels were studied in NSCLC patients. Inter-
estingly, patients with at least one mutation in their lung
tumors possessed a 2-fold higher risk of having a copy
number variation in SOX2. This is to our knowledge the
first study to report an association between TP53 muta-
tions and SOX2 copy number alterations. However,
individuals carrying TP53 mutations show generally
higher levels of germline copy number variation [48].
Furthermore, smoking is known to increase the risk of
acquiring TP53 mutations [49–51] and, similarly, we and
others [34, 36] have demonstrated that smokers have a
higher risk of acquiring SOX2 copy number alterations
in tumors. Hence, TP53 mutations may contribute to
SOX2 copy number alterations in lung cancer patients.
Moreover, a correlation between TP53 and SOX2 ex-
pression levels was observed in NSCLC tumors. To
further investigate this relationship, silencing of TP53
and SOX2 was performed in the lung adenocarcinoma
cell line A427. TP53 knockdown reduced SOX2 mRNA
and protein expression, whereas SOX2 knockdown did
not affect TP53 expression levels, indicating a regulatory
role of TP53 on SOX2 in NSCLC. Considering the role
of SOX2 in tumorigenesis it could be expected that
TP53 knockdown would increase SOX2 expression. In-
deed, Chen et al. have previously shown a reduction in
SOX2 expression following TP53 induction in the TP53-
null NSCLC cell line H1299 [18]. These discrepancies as
well as reports on conflicting effects on NSCLC progno-
sis following SOX2 copy number amplification indicate
that the role of SOX2 in NSCLC is far more complex
than can be explained by histology or TP53 status only.
There is a need to further investigate the mechanisms
of TP53 regulation of SOX2. To address this, the pos-
sible involvement of miRNAs was investigated. This is of
interest as a more prominent role of miRNAs in cancer
development has emerged during recent years and TP53
regulates the expression of several genes through miRNAs
[52, 53]. Hsa-miR-145 is an interesting candidate as TP53
activates expression of hsa-miR-145 which in turn re-
presses SOX2 expression in embryonic stem cells [19–21].
Hsa-miR-145 expression has also been suggested as a
novel marker responsible for relapse in surgically treated
NSCLC [22]. Campayo et al. demonstrated that TP53 may
play a role in modulating hsa-miR-145 expression in
NSCLC, and that patients with mutations in TP53 and low
hsa-miR-145 levels had lower survival in respect to patients
with TP53 wild-type or only mutations in TP53 [22].
We here demonstrated that TP53 knockdown repressed
hsa-miR-145-5p expression in the lung adenocarcinoma
cell line A427, whereas the other miRNAs investigated
were unaffected. miRNAs have previously been believed
to affect gene expression modulation only by negative
regulation of target mRNA. Increasing evidence now indi-
cate that miRNAs oscillate between repression and induc-
tion of gene expression in response to specific cellular
conditions and cofactors [54]. Based on our findings, we
suggest a possible role of hsa-miR-145 as an inducer of
SOX2 expression in NSCLC. It is known that hsa-miR-
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145 exhibits opposite effects on RNA regulation in dif-
ferent cell types. Indeed, hsa-miR-145 mediates gene
upregulation during muscle differentiation [55] and
gene downregulation in osteosarcoma [56]. Other ap-
proaches to further investigate the possible regulation
of TP53 on SOX2 in several different lung cancer cell
lines and in different cellular states are clearly needed,
as well as additional studies to fully understand the
complexity of hsa-miR-145 signaling in lung cancer.
Moreover, hsa-miR-638 has recently come into focus as
another promising candidate, as it has been shown that
hsa-miR-638 regulates SOX2 in NSCLC [57]. Interest-
ingly, hsa-miR-638 is known as a TP53-targeting miRNA
[58], further illustrating the complexity of this signaling.
Conclusions
TP53 mutations were associated with an increased risk of
acquiring a SOX2 copy number amplification in NSCLC.
Furthermore, SOX2 and TP53 expression were correlated
in lung tumors and reduction in TP53 resulted in
decreased SOX2 and hsa-miR-145 expression in lung
adenocarcinoma cells. As hsa-miR-145 has previously
been shown to regulate SOX2 expression, we propose that
one mechanism for the TP53 regulation of SOX2 may be
through hsa-miR-145. This prompts for further studies on
the mechanisms behind TP53-induced regulation of
SOX2 expression and the possible importance of hsa-
miR-145 in lung cancer development.
Additional file
Additional file 1: Table S1. Association between clinicopathological
data and SOX2 gene status in NSCLC tumors. (PDF 101 kb)
Abbreviations
NSCLC: Non-small cell lung cancer; OR: Odds ratio; PAH: Polycyclic aromatic
hydrocarbons.
Competing interests
All authors declare no conflict of interest.
Authors’ contributions
JSE carried out molecular genetic studies, participated in statistical analysis
and drafted the manuscript. VS coordinated the NSCLC databank and carried
out the histopathology and survival analysis. PB and AG participated in the
coordination of collection of healthy controls and commented the initial
manuscript draft. AH participated in the design and coordination of the
study and helped draft the manuscript. SZ led the study, was involved in
TP53 mutational analysis, participated in its design and helped draft the
manuscript. All authors read and approved the final manuscript.
Acknowledgments
Professor Lodve B. Stangeland (University of Bergen, Norway), Professor
David H. Phillips (King’s College, London) and Dr. Steen Mollerup are
acknowledged for their kind contribution in collecting tissue samples,
preparing tissues and analyzing PAH-DNA adducts, respectively. We also
thank Dr. Vegard Eldholm for his support on primer design. Tove
Andreassen and Elin Thorner Einarsdottir are acknowledged for excellent
technical assistance. This study was supported by the Norwegian Cancer
Society.
Author details
1Department of Biological and Chemical Work Environment, National
Institute of Occupational Health, PO Box 8149 Dep, N-0033 Oslo, Norway.
2Department of Clinical Science, University of Bergen, Bergen, Norway.
Received: 28 April 2015 Accepted: 10 January 2016
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin. 2011;61:69–90.
2. Staaf J, Isaksson S, Karlsson A, Jonsson M, Johansson L, Jonsson P, et al.
Landscape of somatic allelic imbalances and copy number alterations in
human lung carcinoma. Int J Cancer. 2013;132:2020–31.
3. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, et al. The transcriptional
landscape and mutational profile of lung adenocarcinoma. Genome Res.
2012;22:2109–19.
4. Iwakawa R, Takenaka M, Kohno T, Shimada Y, Totoki Y, Shibata T, Tsuta K,
Nishikawa R, Noguchi M, Sato-Otsubo A et al. Genome-wide identification
of genes with amplification and/or fusion in small cell lung cancer. Genes
Chromosomes Cancer. 2013;52:802-16.
5. Cancer Genome Atlas Research Network. Comprehensive genomic
characterization of squamous cell lung cancers. Nature. 2012;489:519–25.
6. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer
implications. Nat Rev Cancer. 2009;9:95–107.
7. Henkler F, Stolpmann K, Luch A. Exposure to polycyclic aromatic hydrocarbons:
bulky DNA adducts and cellular responses. EXS. 2012;101:107–31.
8. Llanos S, Efeyan A, Monsech J, Dominguez O, Serrano M. A High-Throughput
Loss-of-Function Screening Identifies Novel p53 Regulators. Cell Cycle.
2006;5:1880–5.
9. Dillon LW, Burrow AA, Wang Y-H. DNA Instability at Chromosomal Fragile
Sites in Cancer. Current Genomics. 2010;11:326–37.
10. Dehan E, Ben-Dor A, Liao W, Lipson D, Frimer H, Rienstein S, et al.
Chromosomal aberrations and gene expression profiles in non-small
cell lung cancer. Lung Cancer. 2007;56:175–84.
11. Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer.
Oncogene. 2002;21:6877–83.
12. Gontan C, de Munck A, Vermeij M, Grosveld F, Tibboel D, Rottier R. Sox2 is
important for two crucial processes in lung development: branching
morphogenesis and epithelial cell differentiation. Dev Biol. 2008;317:296–309.
13. Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, et al. Sex determining
region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed
in the pathogenesis of squamous cell carcinomas of the lung. PLoS
One. 2010;5:e9112.
14. Velcheti V, Schalper K, Yao X, Cheng H, Kocoglu M, Dhodapkar K, et al. High
SOX2 levels predict better outcome in non-small cell lung carcinomas. PLoS
One. 2013;8:e61427.
15. Wilbertz T, Wagner P, Petersen K, Stiedl AC, Scheble VJ, Maier S, et al. SOX2
gene amplification and protein overexpression are associated with better
outcome in squamous cell lung cancer. Mod Pathol. 2011;24:944–53.
16. Sholl LM, Long KB, Hornick JL. Sox2 expression in pulmonary non-small cell
and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol.
2010;18:55–61.
17. Li M, He Y, Dubois W, Wu X, Shi J, Huang J. Distinct regulatory mechanisms
and functions for p53-activated and p53-repressed DNA damage response
genes in embryonic stem cells. Mol Cell. 2012;46:30–42.
18. Chen K, Wu K, Cai S, Zhang W, Zhou J, Wang J, et al. Dachshund Binds p53
to Block the Growth of Lung Adenocarcinoma Cells. Cancer Res. 2013.
19. Jain AK, Allton K, Iacovino M, Mahen E, Milczarek RJ, Zwaka TP, et al. p53
regulates cell cycle and microRNAs to promote differentiation of human
embryonic stem cells. PLoS Biol. 2012;10:e1001268.
20. Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A. The loss of the tumour-
suppressor miR-145 results in the shorter disease-free survival of prostate
cancer patients. Br J Cancer. 2013;108:2573–81.
21. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, et al. p53 represses
c-Myc through induction of the tumor suppressor miR-145. Proc Natl
Acad Sci U S A. 2009;106:3207–12.
22. Campayo M, Navarro A, Vinolas N, Diaz T, Tejero R, Gimferrer JM, et al.
Low miR-145 and high miR-367 are associated with unfavourable prognosis in
resected nonsmall cell lung cancer. Eur Respir J. 2013;41:1172–8.
Samulin Erdem et al. BMC Cancer  (2016) 16:28 Page 8 of 9
23. D'Haene B, Vandesompele J, Hellemans J. Accurate and objective copy
number profiling using real-time quantitative PCR. Methods. 2010;50:262–70.
24. Weaver S, Dube S, Mir A, Qin J, Sun G, Ramakrishnan R, et al. Taking qPCR
to a higher level: Analysis of CNV reveals the power of high throughput
qPCR to enhance quantitative resolution. Methods. 2010;50:271–6.
25. Lind H, Ekstrom PO, Ryberg D, Skaug V, Andreassen T, Stangeland L, et al.
Frequency of TP53 mutations in relation to Arg72Pro genotypes in non
small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:2077–81.
26. Kristensen AT, Bjorheim J, Ekstrom PO. Detection of mutations in exon 8 of
TP53 by temperature gradient 96-capillary array electrophoresis. Biotechniques.
2002;33:650–3.
27. Zienolddiny S, Skaug V, Landvik NE, Ryberg D, Phillips DH, Houlston R, et al.
The TERT-CLPTM1L lung cancer susceptibility variant associates with higher
DNA adduct formation in the lung. Carcinogenesis. 2009;30:1368–71.
28. Ge N, Lin HX, Xiao XS, Guo L, Xu HM, Wang X, et al. Prognostic significance
of Oct4 and Sox2 expression in hypopharyngeal squamous cell carcinoma.
J Transl Med. 2010;8:94.
29. Huang P, Qiu J, Li B, Hong J, Lu C, Wang L, et al. Role of Sox2 and Oct4 in
predicting survival of hepatocellular carcinoma patients after hepatectomy.
Clin Biochem. 2011;44:582–9.
30. Matsuoka J, Yashiro M, Sakurai K, Kubo N, Tanaka H, Muguruma K, et al.
Role of the stemness factors sox2, oct3/4, and nanog in gastric carcinoma.
J Surg Res. 2012;174:130–5.
31. Saigusa S, Mohri Y, Ohi M, Toiyama Y, Ishino Y, Okugawa Y, et al. Podoplanin
and SOX2 expression in esophageal squamous cell carcinoma after
neoadjuvant chemo-radiotherapy. Oncol Rep. 2011;26:1069–74.
32. Wang X, Liang Y, Chen Q, Xu HM, Ge N, Luo RZ, et al. Prognostic
significance of SOX2 expression in nasopharyngeal carcinoma. Cancer
Invest. 2012;30:79–85.
33. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is
an amplified lineage-survival oncogene in lung and esophageal squamous
cell carcinomas. Nat Genet. 2009;41:1238–42.
34. Cai YR, Zhang HQ, Zhang ZD, Mu J, Li ZH. Detection of MET and SOX2
amplification by quantitative real-time PCR in non-small cell lung carcinoma.
Oncol Lett. 2011;2:257–64.
35. Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembele D, et al. SOX2 is
an oncogene activated by recurrent 3q26.3 amplifications in human lung
squamous cell carcinomas. PLoS One. 2010;5:e8960.
36. Sasaki H, Yokota K, Hikosaka Y, Moriyama S, Yano M, Fujii Y. Increased Sox2
copy number in lung squamous cell carcinomas. Exp Ther Med. 2012;3:44–8.
37. Nakatsugawa M, Takahashi A, Hirohashi Y, Torigoe T, Inoda S, Murase M, et al.
SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and
augments the tumorigenicity. Lab Invest. 2011;91:1796–804.
38. Chen S, Xu Y, Chen Y, Li X, Mou W, Wang L, et al. SOX2 gene regulates the
transcriptional network of oncogenes and affects tumorigenesis of human
lung cancer cells. PLoS One. 2012;7:e36326.
39. Xiang R, Liao D, Cheng T, Zhou H, Shi Q, Chuang TS, et al. Downregulation
of transcription factor SOX2 in cancer stem cells suppresses growth and
metastasis of lung cancer. Br J Cancer. 2011;104:1410–7.
40. Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, et al. EGFR/
Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like
side-population cells in non-small cell lung cancer. Mol Cancer. 2012;11:73.
41. McCaughan F, Pole JC, Bankier AT, Konfortov BA, Carroll B, Falzon M, et al.
Progressive 3q amplification consistently targets SOX2 in preinvasive
squamous lung cancer. Am J Respir Crit Care Med. 2010;182:83–91.
42. Lu Y, Futtner C, Rock JR, Xu X, Whitworth W, Hogan BL, et al. Evidence that
SOX2 overexpression is oncogenic in the lung. PLoS One. 2010;5:e11022.
43. Brcic L, Sherer CK, Shuai Y, Hornick JL, Chirieac LR, Dacic S. Morphologic and
Clinicopathologic Features of Lung Squamous Cell Carcinomas Expressing
Sox2. Am J Clin Pathol. 2012;138:712–8.
44. Sholl LM, Barletta JA, Yeap BY, Chirieac LR, Hornick JL. Sox2 protein
expression is an independent poor prognostic indicator in stage I lung
adenocarcinoma. Am J Surg Pathol. 2010;34:1193–8.
45. Hussenet T, du Manoir S. SOX2 in squamous cell carcinoma: amplifying
a pleiotropic oncogene along carcinogenesis. Cell Cycle. 2010;9:1480–6.
46. Toschi L, Finocchiaro G, Nguyen TT, Skokan MC, Giordano L, Gianoncelli L,
et al. Increased SOX2 Gene Copy Number Is Associated with FGFR1 and
PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved
Survival in Early Stage Disease. PLoS One. 2014;9:e95303.
47. Chen Y, Huang Y, Huang Y, Chen J, Wang S, Zhou J. The prognostic value
of SOX2 expression in non-small cell lung cancer: a meta-analysis. PLoS
One. 2013;8:e71140.
48. Shlien A, Tabori U, Marshall CR, Pienkowska M, Feuk L, Novokmet A, et al.
Excessive genomic DNA copy number variation in the Li-Fraumeni cancer
predisposition syndrome. Proc Natl Acad Sci U S A. 2008;105:11264–9.
49. Husgafvel-Pursiainen K, Boffetta P, Kannio A, Nyberg F, Pershagen G,
Mukeria A, et al. p53 mutations and exposure to environmental tobacco
smoke in a multicenter study on lung cancer. Cancer Res. 2000;60:2906–11.
50. Takagi Y, Osada H, Kuroishi T, Mitsudomi T, Kondo M, Niimi T, et al. p53
mutations in non-small-cell lung cancers occurring in individuals without
a past history of active smoking. Br J Cancer. 1998;77:1568–72.
51. Vahakangas KH, Bennett WP, Castren K, Welsh JA, Khan MA, Blomeke B, et
al. p53 and K-ras mutations in lung cancers from former and never-smoking
women. Cancer Res. 2001;61:4350–6.
52. MacNeil AJ, Jiao S-C, McEachern LA, Yang YJ, Dennis A, Yu H, et al. MAPK
Kinase 3 Is a Tumor Suppressor with Reduced Copy Number in Breast
Cancer. Cancer Res. 2014;74:162–72.
53. Fischer U, Heckel D, Michel A, Janka M, Hulsebos T, Meese E. Cloning of a
Novel Transcription Factor-Like Gene Amplified in Human Glioma Including
Astrocytoma Grade I. Hum Mol Genet. 1997;6:1817–22.
54. Valinezhad Orang A, Safaralizadeh R, Kazemzadeh-Bavili M. Mechanisms of
miRNA-Mediated Gene Regulation from Common Downregulation to
mRNA-Specific Upregulation. Int J Genomics. 2014;2014:970607.
55. Cordes KR, Sheehy NT, White M, Berry E, Morton SU, Muth AN, et al.
miR-145 and miR-143 Regulate Smooth Muscle Cell Fate Decisions.
Nature. 2009;460:705–10.
56. Li E, Zhang J, Yuan T, Ma B. miR-145 inhibits osteosarcoma cells proliferation
and invasion by targeting ROCK1. Tumor Biology. 2014;35:7645–50.
57. Park JH, Roeder RG. GAS41 is required for repression of the p53 tumor
suppressor pathway during normal cellular proliferation. Mol Cell Biol.
2006;26:4006–16.
58. Han J, Sun P. The pathways to tumor suppression via route p38. Trends
Biochem Sci. 2007;32:364–71.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Samulin Erdem et al. BMC Cancer  (2016) 16:28 Page 9 of 9
